Sarepta Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Sarepta Therapeutics, Inc. (SRPT) holds an ST Score of 61.3 out of 100 (B), with its strongest factor being Profitability (A+) and its weakest Financial Strength (D). Analysts rate SRPT Buy across 55 ratings with a $23.33 average price target (+0.2% vs the current $20.11).
- Strongest
- ProfitabilityA+
- Weakest
- Financial StrengthD
All factor grades
- ProfitabilityA+
- MomentumA+
- SentimentA+
- ValuationB
- ForecastB
- GrowthC-
- Financial StrengthD
- Piotroski3/9
Contact
SRPT stock: frequently asked questions
What is SRPT's ST Score?
Sarepta Therapeutics, Inc. (SRPT) has an ST Score of 61.3 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is SRPT a buy, sell, or hold?
Wall Street's consensus rating on SRPT is Buy based on 55 analyst ratings. Our own ST Score grades it B (61.3/100). This is data, not investment advice — always do your own research.
What is SRPT's valuation grade?
Sarepta Therapeutics, Inc. (SRPT) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is SRPT's growth grade?
Sarepta Therapeutics, Inc. (SRPT) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is SRPT's profitability grade?
Sarepta Therapeutics, Inc. (SRPT) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is SRPT's financial strength grade?
Sarepta Therapeutics, Inc. (SRPT) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for SRPT?
The average analyst price target for Sarepta Therapeutics, Inc. (SRPT) is $23.33 from 55 analysts, which is +0.2% versus the recent price of $20.11.
What is SRPT's Piotroski score?
Sarepta Therapeutics, Inc. (SRPT) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.